DOCSLIB.ORG

Molecular Genetics and Genotype-Phenotype Correlation Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Molecular genetics and genotype-phenotype correlation of inherited corneal dystrophies Cerys J. Evans University College London Doctor of Philosophy (PhD) Supervisors: Professor Alison Hardcastle and Mr. Stephen Tuft Declaration I, Cerys J. Evans, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 Publications Evans, C.J., Liskova, P., Dudakova, L., Hrabcikova, P., Horinek, A., Jirsova, K., Filipec, M., Hardcastle, A., Davidson, A. and Tuft, S. (2015) ‘Identification of six novel mutations in ZEB1 and description of the associated phenotypes in patients with posterior polymorphous corneal dystrophy 3.’, Annals of Human Genetics, 79(1), pp. 1–9. Liskova, P., Evans, C. J., Davidson, A. E., Zaliova, M., Dudakova, L., Trkova, M., Stranecky, V., Carnt, N., Plagnol, V., Vincent, A. L., Tuft, S. J. and Hardcastle, A. J. (2015) ‘Heterozygous deletions at the ZEB1 locus verify haploinsufficiency as the mechanism of disease for posterior polymorphous corneal dystrophy type 3.’, European Journal of Human Genetics, 24(7), pp. 985–991. Davidson, A., Liskova, P., Evans, C.J., Dudakova, L., Nosková, L., Pontikos, N., Hartmannová, H., Hodaňová, K., Stránecký, V., Kozmík, Z., Levis, H., Idigo, N., Sasai, N., Maher, G., Bellingham, J., Veli, N., Ebenezer, N., Cheetham, M., Daniels, J., Thaung, C., Jirsova, K., Plagnol, V., Filipec, M., Kmoch, S., Tuft, S. and Hardcastle, A. (2015) ‘Autosomal-dominant corneal endothelial dystrophies CHED1 and PPCD1 are allelic disorders caused by non-coding mutations in the promoter of OVOL2.’, The American Journal of Human Genetics, 98(1), pp. 75–89. Evans, C. J., Davidson, A. E., Carnt, N., Rojas López, K. E., Veli, N., Thaung, C. M., Tuft, S. J. and Hardcastle, A. J. (2016) ‘Genotype-phenotype correlation for TGFBI corneal dystrophies identifies p.(G623D) as a novel cause of epithelial basement membrane dystrophy.’, Investigative Ophthalmology & Visual Science, 57(13), pp. 5407–5414. Morantes, S., Evans, C. J., Valencia, A. V, Davidson, A. E., Hardcastle, A. J., Linares, A. R., Tuft, S. J. and Cuevas, M. (2016) ‘Spectrum of clinical signs and genetic characterization of gelatinous drop-like corneal dystrophy in a Colombian family.’, Cornea, 35(8), pp. 1141–11466. 3 Acknowledgements I would like to thank my supervisors, Prof. Alison Hardcastle and Mr. Stephen Tuft, for providing me with the opportunity to undertake this project and for guiding me through the PhD process. I could not have completed this thesis without their unwavering support. I would like to thank all my colleagues at the Institute of Ophthalmology for providing both technical and emotional support throughout the PhD, particularly, Alice Davidson, Sek-Shir Cheong, Naheed Kanuga, Wenwen Li, Nikolas Pontikos, Jessica Gardner and Michael Cheetham. I would also like to thank my collaborator Petra Liskova. I would like to thank Fight for Sight who generously provided the funding for this project. Most importantly, I would like to thank the patients and relatives who donated their samples, without which this project could not have been completed. I hope that the results within this thesis have a positive impact and will contribute to the development of therapies in future. Finally, I would like to thank my family and friends who encouraged me to keep going. 4 Abstract Corneal dystrophies are a group of inherited, primarily monogenic, disorders that compromise the transparency of the cornea and cause visual impairment. A large cohort, consisting of 191 corneal dystrophy probands, was recruited to the study with the aim of investigating the genetic basis of phenotypically heterogeneous corneal dystrophy diagnoses. Following genetic investigation, genotype data was combined with clinical data to investigate genotype-phenotype correlations. The most common cause of corneal dystrophy in this cohort was heterozygous dominant mutations in TGFBI, which were identified in 70 probands with epithelial- stromal dystrophies. The majority of TGFBI mutations displayed genotype- phenotype correlation, however a p.(Gly623Asp) mutation was unexpectedly associated with a broad phenotypic spectrum of disease, including epithelial basement membrane dystrophy (EBMD). There was evidence for additional locus heterogeneity for EBMD; two families were identified in which TGFBI coding mutations were excluded, however no compelling candidate gene(s) were identified following whole exome sequence (WES) analysis. Novel and previously reported mutations in CHST6, UBIAD1 and TACTSD2 were identified for other anterior corneal dystrophies; recessive macular corneal dystrophy, dominant Schnyder corneal dystrophy and recessive gelatinous drop-like dystrophy, respectively. Dominant mutations in ZEB1 were identified in 8 patients with an endothelial dystrophy, posterior polymorphous corneal dystrophy (PPCD3), with novel heterozygous deletions encompassing the ZEB1 gene confirming haploinsufficiency as the mechanism of pathogenicity. 5 Investigation of dominant endothelial dystrophy families using whole genome sequencing (WGS), including PPCD1 and congenital hereditary endothelial dystrophy (CHED1), revealed that mutations in the promoter of OVOL2 are a novel cause of disease and therefore that PPCD1 and CHED1 are allelic disorders. OVOL2 is a transcription factor, which is a direct repressor of ZEB1. OVOL2 was not expressed in normal corneal endothelial cells, therefore it was hypothesised that aberrant expression of OVOL2 in corneal endothelial cells causes transcriptional repression of ZEB1 expression. A novel locus causing dominant PPCD (PPCD4) was identified in a large family from the Czech Republic and linkage analysis and WGS revealed a non-coding mutation in a novel gene as likely to be causative in this family. Interestingly, a proportion of patients clinically diagnosed with a corneal dystrophy were found, on further genetic and clinical investigation, to have an inherited syndrome which was responsible for the presence of corneal opacities, the most common of which was Meretoja syndrome. In some cases, a phenocopy of disease was responsible, including paraproteinemic keratopathy. Genetic screening can therefore significantly improve clinical care for patients and their families. In summary, this study provides insight into the genetic causes of corneal dystrophies including the identification of novel corneal dystrophy genes and mechanisms of disease, which is a pre-requisite for the development of targeted genetic therapies. Furthermore, it provides further understanding of genotype- phenotype correlation for specific corneal dystrophy genes and mutations that can result in improved diagnostic and prognostic accuracy for patients. 6 Contents ABSTRACT 5 LIST OF FIGURES 16 CHAPTER 1: INTRODUCTION 30 1.1 Anatomy of the eye 30 1.2 Structure and function of the cornea 31 1.2.1 Epithelium 32 1.2.2 Bowman’s layer 32 1.2.3 Stroma 32 1.2.4 Descemet’s membrane 33 1.2.5 Endothelium 33 1.2.6 Dua’s layer 34 1.2.7 Corneal nerves 34 1.3 Corneal development 35 1.3.1 Anterior segment development 35 1.3.2 Epithelial development 36 1.3.3 Development of the corneal stroma and endothelium 36 1.4 Corneal homeostasis and wound healing 38 1.4.1 Epithelial homeostasis 38 1.4.2 Stromal homeostasis 39 1.4.3 Epithelium and stromal wound healing 40 1.4.4 Endothelial homeostasis 41 1.4.5 Endothelium wound healing 41 1.5 Corneal dystrophies 41 1.5.1 Overview 41 1.5.2 Clinical diagnosis 42 1.5.3 Management options 43 7 1.6 Genetic techniques 46 1.6.1 Linkage analysis 46 1.6.2 Sanger sequencing 48 1.6.3 Next-generation sequencing 48 1.6.4 Identification of copy number variation 53 1.7 Genetics of corneal dystrophies 55 1.7.1 Anterior corneal dystrophies 55 1.7.2 Endothelial corneal dystrophies 56 1.8 The IC3D classification of corneal dystrophies 57 1.9 Aims of project 61 CHAPTER 2: MATERIALS AND METHODS 63 2.1 Patient recruitment and sample collection 63 2.1.1 Clinical diagnosis 63 2.1.2 Clinical histology 63 2.1.3 DNA extraction from blood 63 2.1.4 DNA extraction from saliva 64 2.1.5 Obtaining DNA samples from additional sites 64 2.2 Sanger sequencing 64 2.2.1 Primer design 64 2.2.2 Polymerase chain reaction 65 2.2.3 Agarose gel electrophoresis 67 2.2.4 PCR purification 67 2.2.5 Sanger sequencing 68 2.3 Assessment of variant pathogenicity 69 2.3.1 Frequency 69 2.3.2 Amino acid conservation 69 2.3.3 Pathogenicity prediction tools 69 2.3.4 Segregation analysis 70 2.3.5 Splice prediction tools 70 8 2.3.6 Transcription factor binding predictions 70 2.4 STS deletion screening 71 2.5 CHST6 deletion and rearrangement screening 71 2.6 Whole exome sequencing 71 2.6.1 Alignment of read data and variant calling 72 2.6.2 Variant filtering strategies of WES data 72 2.6.3 Exome depth 73 2.7 SNP array genotyping for copy number variations 74 2.8 ZEB1 deletion quantitative PCR assay 74 2.8.1 Primer design 74 2.8.2 qPCR reactions 74 2.8.3 qPCR data analysis 75 2.9 ZEB1 deletion breakpoint mapping 75 2.10 Linkage analysis 76 2.11 Whole genome sequencing 76 2.11.1 Alignment of read data and variant calling 77 2.11.2 Variant filtering of WGS data 77 2.11.3 Variant effect predictor 77 2.12 Culturing corneal derived cells 78 2.12.1 Isolation and culturing stromal fibroblasts 78 2.12.2 Culturing limbal epithelial cells 78 2.12.3 Culturing immortalised human corneal epithelial cells 79 2.13 Reverse-transcription PCR 79 2.13.1 RNA extraction from cells 79 2.13.2 cDNA synthesis 79 2.13.3 RT-PCR to investigate
Recommended publications
  • Np63 Activates the Fanconi Anemia DNA Repair Pathway and Limits the Efficacy of Cisplatin Treatment in Squamous Cell Carcinoma Anne Catherine Bretz1, Miriam P

    Np63 Activates the Fanconi Anemia DNA Repair Pathway and Limits the Efficacy of Cisplatin Treatment in Squamous Cell Carcinoma Anne Catherine Bretz1, Miriam P

    3204–3218 Nucleic Acids Research, 2016, Vol. 44, No. 7 Published online 26 January 2016 doi: 10.1093/nar/gkw036 Np63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma Anne Catherine Bretz1, Miriam P. Gittler1,Joel¨ P. Charles1, Niklas Gremke1, Ines Eckhardt1, Marco Mernberger1, Robert Mandic2,Jurgen¨ Thomale3, Andrea Nist4, Michael Wanzel1,5 and Thorsten Stiewe1,4,5,* 1Institute of Molecular Oncology, Philipps-University Marburg, 35043 Marburg, Germany, 2Department of Otorhinolaryngology, Head & Neck Surgery, University Hospital Giessen and Marburg, Philipps-University, 35033 Marburg, Germany, 3Institute of Cell Biology, University Duisburg-Essen, 45122 Essen, Germany, 4Genomics Core Facility, Philipps-University Marburg, 35043 Marburg, Germany and 5Universities of Giessen and Marburg Lung Center, member of the German Center for Lung Research (DZL), 35043 Marburg, Germany Received September 03, 2015; Revised December 18, 2015; Accepted January 12, 2016 ABSTRACT INTRODUCTION TP63, a member of the p53 gene family gene, encodes Squamous cell carcinoma (SCC) is a common and lethal the Np63 protein and is one of the most frequently human cancer, and relatively little progress has been made amplified genes in squamous cell carcinomas (SCC) in improving outcomes for SCC due to a poor understand- of the head and neck (HNSCC) and lungs (LUSC). ing of its underlying molecular pathogenesis (1,2). While Using an epiallelic series of siRNAs with intrinsically SCCs typically lack somatic oncogene-activating mutations, they exhibit frequent amplification of the p53 gene fam- different knockdown abilities, we show that the com- ily member TP63 (1–6). Recent tumor genome sequencing plete loss of Np63 strongly impaired cell prolifera- studies have revealed TP63 amplification in 20–25% of head tion, whereas partial Np63 depletion rendered cells and neck SCC (HNSCC) and 25–50% of lung SCC (LUSC) hypersensitive to cisplatin accompanied by an ac- (4,6).
  • Generation and Characterization of a Novel Mouse Line, Keratocan-Rtta (Kerart), for Corneal Stroma and Tendon Research

    Generation and Characterization of a Novel Mouse Line, Keratocan-Rtta (Kerart), for Corneal Stroma and Tendon Research

    Cornea Generation and Characterization of a Novel Mouse Line, Keratocan-rtTA (KeraRT), for Corneal Stroma and Tendon Research Yujin Zhang,1 Winston W.-Y. Kao,2 Yasuhito Hayashi,3 Lingling Zhang,1 Mindy Call,2 Fei Dong,2 Yong Yuan,2 Jianhua Zhang,2 Yen-Chiao Wang,1 Okada Yuka,1,4 Atsushi Shiraishi,3 and Chia-Yang Liu1 1School of Optometry, Indiana University, Bloomington, Indiana, United States 2Edith J. Crawley Vision Research Center/Department of Ophthalmology, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States 3Department of Ophthalmology, School of Medicine, Ehime University, Ehime, Japan 4Department of Ophthalmology, School of Medicine, Wakayama Medical University, Wakayama, Japan RT Correspondence: Yujin Zhang, Indi- PURPOSE. We created a novel inducible mouse line Keratocan-rtTA (Kera ) that allows ana University School of Optometry, specific genetic modification in corneal keratocytes and tenocytes during development and in 800 Atwater Avenue, Bloomington, adults. IN 47405, USA; [email protected]. METHODS. A gene-targeting vector (Kera- IRES2-rtTA3) was constructed and inserted right after Chia-Yang Liu, Indiana University the termination codon of the mouse Kera allele via gene targeting techniques. The resulting RT RT School of Optometry, 800 Atwater Kera mouse was crossed to tet-O-Hist1H2B-EGFP (TH2B-EGFP) to obtain Kera /TH2B-EGFP Avenue, Bloomington, IN 47405, compound transgenic mice, in which cells expressing Kera are labeled with green USA; fluorescence protein (GFP) by doxycycline (Dox) induction. The expression patterns of [email protected]. RT RT GFP and endogenous Kera were examined in Kera /TH2B-EGFP. Moreover, Kera was bred Submitted: July 21, 2017 with tet-O-TGF-a to generate a double transgenic mouse, KeraRT/tet-O-TGF-a, to overexpress Accepted: August 16, 2017 TGF-a in corneal keratocytes upon Dox induction.
  • A Decision Support System for Reporting High Throughput Sequencing of Cancers in Clinical Diagnostic Laboratories Kenneth D

    A Decision Support System for Reporting High Throughput Sequencing of Cancers in Clinical Diagnostic Laboratories Kenneth D

    Doig et al. Genome Medicine (2017) 9:38 DOI 10.1186/s13073-017-0427-z SOFTWARE Open Access PathOS: a decision support system for reporting high throughput sequencing of cancers in clinical diagnostic laboratories Kenneth D. Doig1,2,3,8*, Andrew Fellowes2, Anthony H. Bell2, Andrei Seleznev2, David Ma2, Jason Ellul1, Jason Li1, Maria A. Doyle1, Ella R. Thompson2,3, Amit Kumar1,6,7, Luis Lara1,3, Ravikiran Vedururu2, Gareth Reid2, Thomas Conway1, Anthony T. Papenfuss1,3,5,6 and Stephen B. Fox2,3,4 Abstract Background: The increasing affordability of DNA sequencing has allowed it to be widely deployed in pathology laboratories. However, this has exposed many issues with the analysis and reporting of variants for clinical diagnostic use. Implementing a high-throughput sequencing (NGS) clinical reporting system requires a diverse combination of capabilities, statistical methods to identify variants, global variant databases, a validated bioinformatics pipeline, an auditable laboratory workflow, reproducible clinical assays and quality control monitoring throughout. These capabilities must be packaged in software that integrates the disparate components into a useable system. Results: To meet these needs, we developed a web-based application, PathOS, which takes variant data from a patient sample through to a clinical report. PathOS has been used operationally in the Peter MacCallum Cancer Centre for two years for the analysis, curation and reporting of genetic tests for cancer patients, as well as the curation of large-scale research studies. PathOS has also been deployed in cloud environments allowing multiple institutions to use separate, secure and customisable instances of the system. Increasingly, the bottleneck of variant curation is limiting the adoption of clinical sequencing for molecular diagnostics.
  • Viewed Under 23 (B) Or 203 (C) fi M M Male Cko Mice, and Largely Unaffected Magni Cation; Scale Bars, 500 M (B) and 50 M (C)

    Viewed Under 23 (B) Or 203 (C) fi M M Male Cko Mice, and Largely Unaffected Magni Cation; Scale Bars, 500 M (B) and 50 M (C)

    BRIEF COMMUNICATION www.jasn.org Renal Fanconi Syndrome and Hypophosphatemic Rickets in the Absence of Xenotropic and Polytropic Retroviral Receptor in the Nephron Camille Ansermet,* Matthias B. Moor,* Gabriel Centeno,* Muriel Auberson,* † † ‡ Dorothy Zhang Hu, Roland Baron, Svetlana Nikolaeva,* Barbara Haenzi,* | Natalya Katanaeva,* Ivan Gautschi,* Vladimir Katanaev,*§ Samuel Rotman, Robert Koesters,¶ †† Laurent Schild,* Sylvain Pradervand,** Olivier Bonny,* and Dmitri Firsov* BRIEF COMMUNICATION *Department of Pharmacology and Toxicology and **Genomic Technologies Facility, University of Lausanne, Lausanne, Switzerland; †Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts; ‡Institute of Evolutionary Physiology and Biochemistry, St. Petersburg, Russia; §School of Biomedicine, Far Eastern Federal University, Vladivostok, Russia; |Services of Pathology and ††Nephrology, Department of Medicine, University Hospital of Lausanne, Lausanne, Switzerland; and ¶Université Pierre et Marie Curie, Paris, France ABSTRACT Tight control of extracellular and intracellular inorganic phosphate (Pi) levels is crit- leaves.4 Most recently, Legati et al. have ical to most biochemical and physiologic processes. Urinary Pi is freely filtered at the shown an association between genetic kidney glomerulus and is reabsorbed in the renal tubule by the action of the apical polymorphisms in Xpr1 and primary fa- sodium-dependent phosphate transporters, NaPi-IIa/NaPi-IIc/Pit2. However, the milial brain calcification disorder.5 How- molecular identity of the protein(s) participating in the basolateral Pi efflux remains ever, the role of XPR1 in the maintenance unknown. Evidence has suggested that xenotropic and polytropic retroviral recep- of Pi homeostasis remains unknown. Here, tor 1 (XPR1) might be involved in this process. Here, we show that conditional in- we addressed this issue in mice deficient for activation of Xpr1 in the renal tubule in mice resulted in impaired renal Pi Xpr1 in the nephron.
  • Universidade Estadual De Campinas Instituto De Biologia

    Universidade Estadual De Campinas Instituto De Biologia

    UNIVERSIDADE ESTADUAL DE CAMPINAS INSTITUTO DE BIOLOGIA VERÔNICA APARECIDA MONTEIRO SAIA CEREDA O PROTEOMA DO CORPO CALOSO DA ESQUIZOFRENIA THE PROTEOME OF THE CORPUS CALLOSUM IN SCHIZOPHRENIA CAMPINAS 2016 1 VERÔNICA APARECIDA MONTEIRO SAIA CEREDA O PROTEOMA DO CORPO CALOSO DA ESQUIZOFRENIA THE PROTEOME OF THE CORPUS CALLOSUM IN SCHIZOPHRENIA Dissertação apresentada ao Instituto de Biologia da Universidade Estadual de Campinas como parte dos requisitos exigidos para a obtenção do Título de Mestra em Biologia Funcional e Molecular na área de concentração de Bioquímica. Dissertation presented to the Institute of Biology of the University of Campinas in partial fulfillment of the requirements for the degree of Master in Functional and Molecular Biology, in the area of Biochemistry. ESTE ARQUIVO DIGITAL CORRESPONDE À VERSÃO FINAL DA DISSERTAÇÃO DEFENDIDA PELA ALUNA VERÔNICA APARECIDA MONTEIRO SAIA CEREDA E ORIENTADA PELO DANIEL MARTINS-DE-SOUZA. Orientador: Daniel Martins-de-Souza CAMPINAS 2016 2 Agência(s) de fomento e nº(s) de processo(s): CNPq, 151787/2F2014-0 Ficha catalográfica Universidade Estadual de Campinas Biblioteca do Instituto de Biologia Mara Janaina de Oliveira - CRB 8/6972 Saia-Cereda, Verônica Aparecida Monteiro, 1988- Sa21p O proteoma do corpo caloso da esquizofrenia / Verônica Aparecida Monteiro Saia Cereda. – Campinas, SP : [s.n.], 2016. Orientador: Daniel Martins de Souza. Dissertação (mestrado) – Universidade Estadual de Campinas, Instituto de Biologia. 1. Esquizofrenia. 2. Espectrometria de massas. 3. Corpo caloso.
  • Transcriptional Regulation of RKIP in Prostate Cancer Progression

    Transcriptional Regulation of RKIP in Prostate Cancer Progression

    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Sciences Transcriptional Regulation of RKIP in Prostate Cancer Progression Submitted by: Sandra Marie Beach In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Sciences Examination Committee Major Advisor: Kam Yeung, Ph.D. Academic William Maltese, Ph.D. Advisory Committee: Sonia Najjar, Ph.D. Han-Fei Ding, M.D., Ph.D. Manohar Ratnam, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: May 16, 2007 Transcriptional Regulation of RKIP in Prostate Cancer Progression Sandra Beach University of Toledo ACKNOWLDEGMENTS I thank my major advisor, Dr. Kam Yeung, for the opportunity to pursue my degree in his laboratory. I am also indebted to my advisory committee members past and present, Drs. Sonia Najjar, Han-Fei Ding, Manohar Ratnam, James Trempe, and Douglas Pittman for generously and judiciously guiding my studies and sharing reagents and equipment. I owe extended thanks to Dr. William Maltese as a committee member and chairman of my department for supporting my degree progress. The entire Department of Biochemistry and Cancer Biology has been most kind and helpful to me. Drs. Roy Collaco and Hong-Juan Cui have shared their excellent technical and practical advice with me throughout my studies. I thank members of the Yeung laboratory, Dr. Sungdae Park, Hui Hui Tang, Miranda Yeung for their support and collegiality. The data mining studies herein would not have been possible without the helpful advice of Dr. Robert Trumbly. I am also grateful for the exceptional assistance and shared microarray data of Dr.
  • Nuclear Organization and the Epigenetic Landscape of the Mus Musculus X-Chromosome Alicia Liu University of Connecticut - Storrs, Alicia.Liu@Uconn.Edu

    Nuclear Organization and the Epigenetic Landscape of the Mus Musculus X-Chromosome Alicia Liu University of Connecticut - Storrs, [email protected]

    University of Connecticut OpenCommons@UConn Doctoral Dissertations University of Connecticut Graduate School 8-9-2019 Nuclear Organization and the Epigenetic Landscape of the Mus musculus X-Chromosome Alicia Liu University of Connecticut - Storrs, [email protected] Follow this and additional works at: https://opencommons.uconn.edu/dissertations Recommended Citation Liu, Alicia, "Nuclear Organization and the Epigenetic Landscape of the Mus musculus X-Chromosome" (2019). Doctoral Dissertations. 2273. https://opencommons.uconn.edu/dissertations/2273 Nuclear Organization and the Epigenetic Landscape of the Mus musculus X-Chromosome Alicia J. Liu, Ph.D. University of Connecticut, 2019 ABSTRACT X-linked imprinted genes have been hypothesized to contribute parent-of-origin influences on social cognition. A cluster of imprinted genes Xlr3b, Xlr4b, and Xlr4c, implicated in cognitive defects, are maternally expressed and paternally silent in the murine brain. These genes defy classic mechanisms of autosomal imprinting, suggesting a novel method of imprinted gene regulation. Using Xlr3b and Xlr4c as bait, this study uses 4C-Seq on neonatal whole brain of a 39,XO mouse model, to provide the first in-depth analysis of chromatin dynamics surrounding an imprinted locus on the X-chromosome. Significant differences in long-range contacts exist be- tween XM and XP monosomic samples. In addition, XM interaction profiles contact a greater number of genes linked to cognitive impairment, abnormality of the nervous system, and abnormality of higher mental function. This is not a pattern that is unique to the imprinted Xlr3/4 locus. Additional Alicia J. Liu - University of Connecticut - 2019 4C-Seq experiments show that other genes on the X-chromosome, implicated in intellectual disability and/or ASD, also produce more maternal contacts to other X-linked genes linked to cognitive impairment.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Distinguishing Pleiotropy from Linked QTL Between Milk Production Traits

    Distinguishing Pleiotropy from Linked QTL Between Milk Production Traits

    Cai et al. Genet Sel Evol (2020) 52:19 https://doi.org/10.1186/s12711-020-00538-6 Genetics Selection Evolution RESEARCH ARTICLE Open Access Distinguishing pleiotropy from linked QTL between milk production traits and mastitis resistance in Nordic Holstein cattle Zexi Cai1*†, Magdalena Dusza2†, Bernt Guldbrandtsen1, Mogens Sandø Lund1 and Goutam Sahana1 Abstract Background: Production and health traits are central in cattle breeding. Advances in next-generation sequencing technologies and genotype imputation have increased the resolution of gene mapping based on genome-wide association studies (GWAS). Thus, numerous candidate genes that afect milk yield, milk composition, and mastitis resistance in dairy cattle are reported in the literature. Efect-bearing variants often afect multiple traits. Because the detection of overlapping quantitative trait loci (QTL) regions from single-trait GWAS is too inaccurate and subjective, multi-trait analysis is a better approach to detect pleiotropic efects of variants in candidate genes. However, large sample sizes are required to achieve sufcient power. Multi-trait meta-analysis is one approach to deal with this prob- lem. Thus, we performed two multi-trait meta-analyses, one for three milk production traits (milk yield, protein yield and fat yield), and one for milk yield and mastitis resistance. Results: For highly correlated traits, the power to detect pleiotropy was increased by multi-trait meta-analysis com- pared with the subjective assessment of overlapping of single-trait QTL confdence intervals. Pleiotropic efects of lead single nucleotide polymorphisms (SNPs) that were detected from the multi-trait meta-analysis were confrmed by bivariate association analysis. The previously reported pleiotropic efects of variants within the DGAT1 and MGST1 genes on three milk production traits, and pleiotropic efects of variants in GHR on milk yield and fat yield were con- frmed.
  • Comparative Analysis of a Teleost Skeleton Transcriptome Provides Insight Into Its Regulation

    Comparative Analysis of a Teleost Skeleton Transcriptome Provides Insight Into Its Regulation

    Accepted Manuscript Comparative analysis of a teleost skeleton transcriptome provides insight into its regulation Florbela A. Vieira, M.A.S. Thorne, K. Stueber, M. Darias, R. Reinhardt, M.S. Clark, E. Gisbert, D.M. Power PII: S0016-6480(13)00264-5 DOI: http://dx.doi.org/10.1016/j.ygcen.2013.05.025 Reference: YGCEN 11541 To appear in: General and Comparative Endocrinology Please cite this article as: Vieira, F.A., Thorne, M.A.S., Stueber, K., Darias, M., Reinhardt, R., Clark, M.S., Gisbert, E., Power, D.M., Comparative analysis of a teleost skeleton transcriptome provides insight into its regulation, General and Comparative Endocrinology (2013), doi: http://dx.doi.org/10.1016/j.ygcen.2013.05.025 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 1 Comparative analysis of a teleost skeleton transcriptome 2 provides insight into its regulation 3 4 Florbela A. Vieira1§, M. A. S. Thorne2, K. Stueber3, M. Darias4,5, R. Reinhardt3, M. 5 S. Clark2, E. Gisbert4 and D. M. Power1 6 7 1Center of Marine Sciences, Universidade do Algarve, Faro, Portugal. 8 2British Antarctic Survey – Natural Environment Research Council, High Cross, 9 Madingley Road, Cambridge, CB3 0ET, UK.
  • FAM83A and FAM83B As Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC

    FAM83A and FAM83B As Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC

    cancers Article FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC Sarah Richtmann 1,2 , Dennis Wilkens 3, Arne Warth 4, Felix Lasitschka 4, Hauke Winter 2,5, Petros Christopoulos 2,6 , Felix J. F. Herth 2,7, Thomas Muley 1,2, Michael Meister 1,2 and Marc A. Schneider 1,2,* 1 Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, D-69126 Heidelberg, Germany; [email protected] (S.R.); [email protected] (T.M.); [email protected] (M.M.) 2 Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), D-69120 Heidelberg, Germany; [email protected] (H.W.); [email protected] (P.C.); [email protected] (F.J.F.H.) 3 Microbial Energy Conversion and Biotechnology, Department of Biology, Technische Universität Darmstadt, D-64287 Darmstadt, Germany; [email protected] 4 Institute of Pathology, Heidelberg University Hospital, D-69120 Heidelberg, Germany; [email protected] (A.W.); [email protected] (F.L.) 5 Department of Surgery, Thoraxklinik at Heidelberg University Hospital, D-69126 Heidelberg, Germany 6 Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, D-69126 Heidelberg, Germany 7 Department of Pneumology and Critical Care Medicine, Thoraxklinik at Heidelberg University Hospital, D-69126 Heidelberg, Germany * Correspondence: [email protected] Received: 27 March 2019; Accepted: 9 May 2019; Published: 11 May 2019 Abstract: Although targeted therapy has improved the survival rates in the last decade, non-small-cell lung cancer (NSCLC) is still the most common cause of cancer-related death.
  • FAM83 Family Oncogenes Are Broadly Involved in Human Cancers: an Integrative Multi-Omics Approach Antoine M

    FAM83 Family Oncogenes Are Broadly Involved in Human Cancers: an Integrative Multi-Omics Approach Antoine M

    FAM83 family oncogenes are broadly involved in human cancers: an integrative multi-omics approach Antoine M. Snijders1, Sun-Young Lee1, Bo Hang1, Wenshan Hao2, Mina J. Bissell1 and Jian-Hua Mao1 1 Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, CA, USA 2 Nanjing Biotech and Pharmaceutical Valley Development Center, China Keywords The development of novel targeted therapies for cancer treatment requires copy number variation; FAM83 family; gene identification of reliable targets. FAM83 (‘family with sequence similarity mutation; multi-omics approach; oncogenes 83’) family members A, B, and D were shown recently to have oncogenic potential. However, the overall oncogenic abilities of FAM83 family genes Correspondence J.-H. Mao, A. M. Snijders and M. J. Bissell, remain largely unknown. Here, we used a systematic and integrative geno- Biological Systems and Engineering mics approach to investigate oncogenic properties of the entire FAM83 fam- Division, Lawrence Berkeley National ily members. We assessed transcriptional expression patterns of eight Laboratory, 1 Cyclotron Road, Berkeley, CA FAM83 family genes (FAM83A-H) across tumor types, the relationship 94720, USA between their expression and changes in DNA copy number, and the associa- E-mails: [email protected]; tion with patient survival. By comparing the gene expression levels of [email protected] and [email protected] FAM83 family members in cancers from 17 different tumor types with those (Received 5 August 2016, revised 16 in their corresponding normal tissues, we identified consistent upregulation September 2016, accepted 21 October of FAM83D and FAM83H across the majority of tumor types, which is lar- 2016, available online 9 January 2017) gely driven by increased DNA copy number.